Physician profile
John Bennett Westfall
NPI 1467029546
$1,216.27
in general payments reported to CMS, 2019-2025
22 companies · $952 in 2025
The $952 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $36.45 · 2024: $228 · 2025: $952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,162 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,162.44 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $209.46 | 2024-2025 | Winrevair, Zerbaxa, Keytruda |
| Insmed, INC. | $177.03 | 2024-2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $124.77 | 2025 | Yupelri |
| Verona Pharma, INC. | $90.37 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $80.53 | 2024-2025 | Prolastin-C Liquid |
| Bayer Healthcare Pharmaceuticals INC. | $67.77 | 2025 | |
| Edwards Lifesciences Corporation | $58.09 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| United Therapeutics Corporation | $51.18 | 2024-2025 | Tyvaso, Tyvaso |
| Glaxosmithkline, LLC. | $50.39 | 2022-2024 | Arexvy, Trelegy Ellipta |
| Actelion Pharmaceuticals US, INC. | $45.88 | 2024-2025 | Opsumit |
| Astrazeneca Pharmaceuticals LP | $37.65 | 2025 | Wainua, Fasenra |
| E.R. Squibb & Sons, L.L.C. | $31.00 | 2025 | Eliquis |
| Alnylam Pharmaceuticals INC. | $25.69 | 2025 | Onpattro |
| Amgen INC. | $25.55 | 2024 | Tavneos |
| La Jolla Pharmaceutical Company | $24.49 | 2025 | Giapreza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $20.28 | 2025 | |
| Vifor Pharma, INC. | $18.41 | 2025 | Zemaira |
| Mylan Specialty L.P. | $17.80 | 2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.82 | 2025 | Ofev |
| Ani Pharmaceuticals, INC. | $15.53 | 2025 | Purified Cortrophin Gel |
| Philips North America LLC | $14.96 | 2024 | (Ak6) Vest Therapy |
| Abiomed | $13.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Westfall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.